ICON plc’s Post

Are you involved in the medical device sector? Want to stay ahead of the curve with the latest regulatory updates? Then don't miss our upcoming webinar. Industry experts will delve into the recent extensions to the In Vitro Diagnostic Regulation (IVDR) and what they mean for you. Speakers: Dr. Julien Senac, Ph.D., Sue Spencer, and Erik Vollebregt #IVDR #webinar LGC Biosearch Technologies

🚀 Elevate Your Knowledge: Join our webinar "Considerations for Navigating ISO 22442-3 Viral Inactivation Studies" Delve into the intricacies of medical devices using preclinical model tissues and their derivatives with NAMSA's experts! Key Discussion Points: - Various applications of preclinical model tissues in medical devices - The critical need for viral inactivation testing - Customizing studies and overcoming associated challenges - Molecular screening and batch release considerations Don't miss out on crucial insights! Save your spot now. 📆👉https://lnkd.in/emn6wQfN #MedicalDevices #ISO22442 #ViralInactivation #RegulatoryCompliance #NAMSAknows

🚀 Elevate Your Knowledge: Join our webinar "Considerations for Navigating ISO 22442-3 Viral Inactivation Studies" Delve into the intricacies of medical devices using preclinical model tissues and their derivatives with NAMSA's experts! Key Discussion Points: - Various applications of preclinical model tissues in medical devices - The critical need for viral inactivation testing - Customizing studies and overcoming associated challenges - Molecular screening and batch release considerations Don't miss out on crucial insights! Save your spot now. 📆👉https://lnkd.in/emn6wQfN #MedicalDevices #ISO22442 #ViralInactivation #RegulatoryCompliance #NAMSAknows

I invite you to the NAMSA webinar for insights surrounding ISO 22442-3. Bring your questions for the open Q&A session for answers from our industry leading experts - see you there!

🚀 Elevate Your Knowledge: Join our webinar "Considerations for Navigating ISO 22442-3 Viral Inactivation Studies" Delve into the intricacies of medical devices using preclinical model tissues and their derivatives with NAMSA's experts! Key Discussion Points: - Various applications of preclinical model tissues in medical devices - The critical need for viral inactivation testing - Customizing studies and overcoming associated challenges - Molecular screening and batch release considerations Don't miss out on crucial insights! Save your spot now. 📆👉https://lnkd.in/emn6wQfN #MedicalDevices #ISO22442 #ViralInactivation #RegulatoryCompliance #NAMSAknows

🚀 Elevate Your Knowledge: Join our webinar "Considerations for Navigating ISO 22442-3 Viral Inactivation Studies" Delve into the intricacies of medical devices using preclinical model tissues and their derivatives with NAMSA's experts! Key Discussion Points: - Various applications of preclinical model tissues in medical devices - The critical need for viral inactivation testing - Customizing studies and overcoming associated challenges - Molecular screening and batch release considerations Don't miss out on crucial insights! Save your spot now. 📆👉https://lnkd.in/emn6wQfN #MedicalDevices #ISO22442 #ViralInactivation #RegulatoryCompliance #NAMSAknows

🚀 Elevate Your Knowledge: Join our webinar "Considerations for Navigating ISO 22442-3 Viral Inactivation Studies" Delve into the intricacies of medical devices using preclinical model tissues and their derivatives with NAMSA's experts! Key Discussion Points: - Various applications of preclinical model tissues in medical devices - The critical need for viral inactivation testing - Customizing studies and overcoming associated challenges - Molecular screening and batch release considerations Don't miss out on crucial insights! Save your spot now. 📆👉 https://lnkd.in/emn6wQfN #MedicalDevices #ISO22442 #ViralInactivation #RegulatoryCompliance #NAMSAknows

Want to learn more about BARDA DRIVe’s ImmuneChip+ program? Join us for a webinar on September 7, 2023 11:30 a.m. - 1 p.m. ET to hear an overview of current funding opportunities in the program. The event will include a Q&A session for prospective applicants. DRIVe has opened a new area of interest (AOI) under the Broad Agency Announcement (BAA) solicitation for the development of advanced microphysiological systems (MPS), otherwise known as tissue or organ-on-a-chip platforms, as part of ongoing technology development in the ImmuneChip+ Program. We are seeking proposals to develop fully mature tissue chips with immune system capability. Our goal is to engineer advanced in vitro platforms that mimic components and interactions of vital human tissues and the immune system, integrate multiple tissue models, and can reproduce existing clinical results. Register for the event: https://ow.ly/MmyG50PEXeM

Want to learn more about BARDA DRIVe’s ImmuneChip+ program? Join us for a webinar on September 7, 2023 11:30 a.m. - 1 p.m. ET to hear an overview of current funding opportunities in the program. The event will include a Q&A session for prospective applicants. DRIVe has opened a new area of interest (AOI) under the Broad Agency Announcement (BAA) solicitation for the development of advanced microphysiological systems (MPS), otherwise known as tissue or organ-on-a-chip platforms, as part of ongoing technology development in the ImmuneChip+ Program. We are seeking proposals to develop fully mature tissue chips with immune system capability. Our goal is to engineer advanced in vitro platforms that mimic components and interactions of vital human tissues and the immune system, integrate multiple tissue models, and can reproduce existing clinical results. Register for the event: https://ow.ly/MmyG50PEXeM

Introducing the Xpert® Xpress MVP by Cepheid! We are excited to share that the Xpert® Xpress MVP is a CLIA-waived, FDA-cleared PCR test designed to diagnose vaginal infections, including bacterial vaginosis, yeast vaginitis, and trichomoniasis, all within an hour. Utilizing the powerful GeneXpert® system, this test delivers rapid and accurate results, helping healthcare providers make timely treatment decisions. 🔍 Key Features: ✅ Detects organisms associated with bacterial vaginosis, Candida species (including C. glabrata and C. krusei) causing vulvovaginal candidiasis, and Trichomonas vaginalis from a single sample. ✅ Ideal for both laboratories and point-of-care settings due to its ease of use, high sensitivity, and specificity. ✅ Provides actionable diagnostic information within just 60 minutes. The Xpert® Xpress MVP enhances workflow efficiency, ensuring accurate differential diagnoses and improving clinical outcomes through appropriate and timely treatment. Learn more about how Xpert® Xpress MVP can revolutionize your diagnostic capabilities! Contact us at sales@ryvex.net. #HealthcareInnovation #DiagnosticTesting #VaginalHealth #sexualhealth #PCRTesting #Healthcare #genexpert #molecular #laboratory #clia #fda #Cepheid #Danaher #Ryvex 🔗 https://lnkd.in/ezrZfQRx